Belgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development.
https://european-biotechnology.com/wp-content/uploads/2024/04/Scotland.jpg7681280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-11-19 06:17:342024-11-19 06:17:34ATB Therapeutics raises €54m in Series A financing